Tsai KC, Huang YC, Liaw CC, Tsai CI, Chiou CT, Lin CJ, Wei WC, Lin SJ, Tseng YH, Yeh KM, Lin YL, Jan JT, Liang JJ, Liao CC, Chiou WF, Kuo YH, Lee SM, Lee MY, Su YC. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed Pharmacother. (2021) Jan;133:111037. doi: 10.1016/j.biopha.2020.111037. https://doi.org/10.1016/j.biopha.2020.111037
Wei WC, Liaw CC, Tsai KC, Chiou CT, Tseng YH, Chiou WF, Lin YC, Tsai CI, Lin CS, Lin CS, Liou KT, Yu IS, Shen YC*, and Su YC*. Targeting spike protein-induced TLR/NET axis by Covid-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. Pharmacol Res. (2022) Sep 2:106424. doi: 10.1016/j.phrs.2022.106424. https://doi.org/10.1016/j.phrs.2022.106424
Tseng YH, Lin SJ, Hou SM, Wang CH, Cheng SP, Tseng KY, Lee MY, Lee SM, Huang YC, Lin CJ, Lin CK, Tsai TL, Lin CS, Cheng MH, Fong TS, Tsai CI, Lu YW, Lin JC, Huang YW, Hsu WC, Kuo HH, Wang LH, Liaw CC, Wei WC, Tsai KC, Shen YC, Chiou WF, Lin JG, Su YC. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacol Res. (2022) Aug 23;184:106412. doi: 10.1016/j.phrs.2022.106412. https://doi.org/10.1016/j.phrs.2022.106412
Su YC, Huang GJ, Lin JG. Chinese herbal prescriptions for COVID-19 management: Special reference to Taiwan Chingguan Yihau (NRICM101) (2022). Front Pharmacol . 2022 Oct 5:13:928106. doi: 10.3389/fphar.2022.928106. eCollection 2022. https://doi.org/10.3389/fphar.2022.928106
Lin JG, Huang GJ, Su YC. Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19. (2023) J Biomed Sci. 2023 May 3;30(1):30. doi: 10.1186/s12929-023-00923-5. https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-023-00923-5
Ho ST, Tsai YN, Su YC. The development and application of NRICM101 and NRICM102 for the treatment of COVID-19. (2023) J Formos Med Assoc. 2023 Jul;122(7):525-527. doi: 10.1016/j.jfma.2023.04.015. Epub 2023 Apr 26. https://www.sciencedirect.com/science/article/pii/S0929664623001419
Chang CC, Wang YH, Yen JC, Liaw CC, Tsai KC, Wei WC, Chiou WF, Chiou CT, Liou KT, Shen YC*, Su YC*. NRICM101 in combatting COVID-19 induced brain fog: Neuroprotective effects and neurovascular integrity preservation in hACE2 mice. (2025) Journal of Traditional and Complementary Medicine. 2025, 15(1)https://www.sciencedirect.com/science/article/pii/S2225411024000841
Tseng, Y.H.; Huang, Y.C.; Liaw, C.C.; Su, Y.C. Use of NRICM101 for COVID-19 in Taiwan: A Cross-sectional Survey J. Formos. Med. Assoc. 2025. (In Press) https://doi.org/10.1016/j.jfma.2025.07.025
Shen, Y.C.; Wang, Y.H.; Liou, K.T.; Cheng, J.J.; Liu, H.K.; Huang, N.K.; Lo, I-W.; Chang, C.C.; Chiou, W.F.; Tsai, K.C.; Wei, W.C.; Chiou, C.T.; Liaw, C.C.; Su, Y.C. Synergistic Protective Effects of TCM Formula NRICM102 and N-acetylcysteine Against Hepatorenal Injury in a Mouse Model of Bongkrekic Acid Poisoning. Front. Pharmacol. 2025, 16, 1596785. https://doi.org/10.3389/fphar.2025.1596785
Chiou, C.T.; Chang, C.L.; Tseng, Y.H.; Liao, G.Y.; Liao, J.W.; Shen, Y.C.; Wei, W.C.; Tsai, K.C.; Huang, Y.C.; Chang, W.C.; Chiou, W.F.; Liaw, C.C.; Su, Y.C. Toxicological Assessment of Novel Anti-COVID Traditional Chinese Medicine Formulae NRICM101 and NRICM102: A Comprehensive Study on safety and Genotoxicity. Front. Pharmacol. 2025. (Aceppted) https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1596369/abstract
